| Joseph P Mathew, MD | |
|
2408 4 Mile Rd, Racine, WI 53402-2091 | |
| (262) 687-5995 | |
| Not Available |
| Full Name | Joseph P Mathew |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 30 Years |
| Location | 2408 4 Mile Rd, Racine, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023031853 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 40811-020 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension At Home | Milwaukee, WI | Home health agency |
| Ascension All Saints Hospital | Racine, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wheaton Franciscan Medical Group Inc | 8628980943 | 594 |
News Archive
The ability to form blood vessels is one of evolution's crowning achievements, and something that separates vertebrates (animals with a backbone) from the rest of the animal kingdom.
BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has obtained Humanitarian Device Exemption (HDE) marketing approval for the BSD-2000 Hyperthermia System (BSD-2000) from the U.S. Food and Drug Administration.
Today at the Society of Gynecologic Oncology (SGO) 43rd Annual Meeting on Women's Cancer®, Dr. Jonathan Ledermann, Director of Cancer Services and Professor of Medical Oncology at University College London, presented new data updating the overall survival of women enrolled in a "Phase II randomized placebo-controlled study of olaparib (AZD2281) maintenance in patients with platinum-sensitive relapsed serous ovarian cancer."
The National Science Advisory Board for Biosecurity (NSABB) is scheduled this week to hold "a closed-door meeting to once again look at unpublished manuscripts describing" two studies that showed how H5N1 bird flu virus could be manipulated to become transmissible among ferrets, a model for humans, NPR's health blog "Shots" reports, noting that the meeting "will include a classified briefing from the intelligence community."
Researchers from the Sinai Center for Thrombosis Research presented findings from a Phase 2a trial substudy that examined the antiplatelet effects of CSL112, a novel apolipoprotein A-I (apo A-I) infusion therapy, at the American Heart Association 2013 Scientific Sessions.
› Verified 5 days ago
| Entity Name | Ascension Medical Group-southeast Wisconsin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609881077 PECOS PAC ID: 8628980943 Enrollment ID: O20031104000421 |
News Archive
The ability to form blood vessels is one of evolution's crowning achievements, and something that separates vertebrates (animals with a backbone) from the rest of the animal kingdom.
BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has obtained Humanitarian Device Exemption (HDE) marketing approval for the BSD-2000 Hyperthermia System (BSD-2000) from the U.S. Food and Drug Administration.
Today at the Society of Gynecologic Oncology (SGO) 43rd Annual Meeting on Women's Cancer®, Dr. Jonathan Ledermann, Director of Cancer Services and Professor of Medical Oncology at University College London, presented new data updating the overall survival of women enrolled in a "Phase II randomized placebo-controlled study of olaparib (AZD2281) maintenance in patients with platinum-sensitive relapsed serous ovarian cancer."
The National Science Advisory Board for Biosecurity (NSABB) is scheduled this week to hold "a closed-door meeting to once again look at unpublished manuscripts describing" two studies that showed how H5N1 bird flu virus could be manipulated to become transmissible among ferrets, a model for humans, NPR's health blog "Shots" reports, noting that the meeting "will include a classified briefing from the intelligence community."
Researchers from the Sinai Center for Thrombosis Research presented findings from a Phase 2a trial substudy that examined the antiplatelet effects of CSL112, a novel apolipoprotein A-I (apo A-I) infusion therapy, at the American Heart Association 2013 Scientific Sessions.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph P Mathew, MD 2408 4 Mile Rd, Racine, WI 53402-2091 Ph: (262) 687-5995 | Joseph P Mathew, MD 2408 4 Mile Rd, Racine, WI 53402-2091 Ph: (262) 687-5995 |
News Archive
The ability to form blood vessels is one of evolution's crowning achievements, and something that separates vertebrates (animals with a backbone) from the rest of the animal kingdom.
BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has obtained Humanitarian Device Exemption (HDE) marketing approval for the BSD-2000 Hyperthermia System (BSD-2000) from the U.S. Food and Drug Administration.
Today at the Society of Gynecologic Oncology (SGO) 43rd Annual Meeting on Women's Cancer®, Dr. Jonathan Ledermann, Director of Cancer Services and Professor of Medical Oncology at University College London, presented new data updating the overall survival of women enrolled in a "Phase II randomized placebo-controlled study of olaparib (AZD2281) maintenance in patients with platinum-sensitive relapsed serous ovarian cancer."
The National Science Advisory Board for Biosecurity (NSABB) is scheduled this week to hold "a closed-door meeting to once again look at unpublished manuscripts describing" two studies that showed how H5N1 bird flu virus could be manipulated to become transmissible among ferrets, a model for humans, NPR's health blog "Shots" reports, noting that the meeting "will include a classified briefing from the intelligence community."
Researchers from the Sinai Center for Thrombosis Research presented findings from a Phase 2a trial substudy that examined the antiplatelet effects of CSL112, a novel apolipoprotein A-I (apo A-I) infusion therapy, at the American Heart Association 2013 Scientific Sessions.
› Verified 5 days ago
Tom M Murphy, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1848 Raintree Ln, Racine, WI 53406 Phone: 262-687-8525 | |
Michael Mullane, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1151 Warwick Way, Racine, WI 53406 Phone: 262-886-7360 Fax: 262-886-7361 | |
David Galbis-reig, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3801 Spring St, Racine, WI 53405 Phone: 262-687-4011 | |
John F. Brennan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3803 Spring Street, Suite 600, Racine, WI 53405 Phone: 262-687-8312 Fax: 262-687-8796 | |
Gerald Wisniewski, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Main St, Racine, WI 53403 Phone: 262-687-6100 | |
Dr. Roger O Boye, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3803 Spring Street, Suite 600, Racine, WI 53405 Phone: 262-687-8312 Fax: 262-687-8312 |